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Abstract
Background: Significant weight loss and malnutrition are common in patients with head and neck cancer, despite
advances in treatment and development of evidenced-based guidelines. The aim of this study was to assess adherence
to evidenced-based guidelines and investigate nutrition outcomes during and post radiation treatment in head and
neck cancer patients.
Methods: This was a two-year retrospective cohort study of 209 head and neck cancer patients (85% male) treated
with ≥20 fractions of radiation (mean dose = 64.8 Gy delivered over 31.9 fractions) at an Australian tertiary hospital.
Results: Regarding guideline adherences, 80% of patients were seen by a dietitian weekly during treatment and 62%
of patients were seen bi-weekly for six-weeks post-treatment. Average weight loss was 6.7% during treatment and 10.
3% three-months post treatment. At the end of treatment, oropharyngeal and oral cavity patients had lost the most
weight (8.8, 10.9%), with skin cancer and laryngeal patients losing the least weight (4.8, 2.9%). Gastrostomy patients
(n = 60) had their tube in-situ for an average of 150 days and lost an average of 7.7 kg (9.4%) during treatment and 11.
5 kg (13.5%) from baseline to three-months post treatment. The number of malnourished patients increased from 15% at
baseline to 56% at the end of treatment, decreasing to 30% three-months post treatment.
Conclusions: Despite high adherence to evidenced-based guidelines, large discrepancies in weight loss and nutritional
status between tumor sites was seen. This highlights the opportunity for further investigation of the relationship between
tumor site, nutritional status and nutrition interventions, which may then influence future evidenced-based guidelines.
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Background
As the global incidence of head and neck cancer (HNC)
increases, there is a corresponding rise in clinician con-
cern for maximising patient nutritional status [1]. The
proximity of tumors to structures vital in mastication
and deglutition often result in patients being unable to
meet their nutrition and hydration requirements orally
[2]. Complications of HNC can include dysphagia, ody-
nophagia, impaired saliva production and changes in
speech and breathing [3, 4]. Approximately 25–50% of
HNC patients have a significant decrease in dietary in-
take prior to the commencement of anti-cancer therapy,
due to the cancer directly affecting function of the upper
aero-digestive tract [5]. In addition, most patients lose in
excess of 5% body weight prior to the commencement of
treatment [6] and are likely to lose at least 10% of their
body weight during treatment, contributing to high rates
of protein-energy malnutrition (PEM) [5]. PEM is asso-
ciated with decreased quality of life, decreased effective-
ness of treatment (due to treatment disruptions),
increased healthcare costs associated with unplanned
hospital admissions, and may negatively impact survival
in HNC [7, 8].
Dietetic interventions can help HNC patients meet their
nutrition requirements while they are experiencing toxic-
ities of radiotherapy or chemo-radiotherapy [9, 10]. Inter-
ventions may include high energy-high protein diets, oral
nutrition supplementation and enteral tube feeding. There
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are two main strategies for enteral feeding in HNC pa-
tients, a nasogastric tube (NGT) and a gastrostomy tube,
both of which have demonstrated effectiveness in achiev-
ing optimal nutritional intake in this population [11]. Pro-
active placement of a gastrostomy tube is seen as the
optimal method to reduce unplanned hospital admissions
and treatment interruptions [3], with early intervention
associated with improved treatment tolerance, nutritional
status, and fewer unplanned hospital admissions [2]. To
assist clinicians in achieving the best possible outcomes
for HNC patients, both the Clinical Oncology Society of
Australia (COSA) and the Royal Brisbane Women’s Hos-
pital (RBWH) have developed evidenced-based guidelines
[12, 13]. These guidelines include care pathways for HNC
patients based on proposed treatments and severity of
malnutrition and dysphagia at diagnosis, and provide rec-
ommendations for frequency of dietetic care, goals and
nutrition interventions.
Despite the introduction of HNC nutritional manage-
ment guidelines, there is still debate among clinicians as to
what the best nutrition interventions for patients are, due
to differences in professional judgement and difficulties
adopting evidenced-based guidelines into practice [13, 14].
It is also unclear how well institutions are able to imple-
ment and follow evidence-based guidelines in clinical prac-
tice. The aims of this study were to determine local
adherence to the RBWH ‘Swallowing and Nutrition Man-
agement Guidelines for Patients with Head and Neck Can-
cer’ [12] and the COSA ‘Evidence-based practice guidelines
for the nutritional management of adult patients with Head
and Neck Cancer’ [13], and to determine local nutrition
outcomes pre-treatment, at the completion of treatment,
one-month post and three-months post treatment.
Methods
Study design
Data were retrieved from electronic medical records of
HNC patients treated at a single tertiary facility. Partici-
pants were eligible for inclusion if they were 18 years or
older and received ≥20 fractions of definitive or high dose
palliative intent radiation treatment to the head and neck
area. Treatment was scheduled on 5 days per week, within
a two-year period between the 1st April 2014 and the 31st
of March 2016. Ethical clearance was received from the
Gold Coast Hospital and Health Service Human Research
Ethics and University Committees.
Standard care
The facility has a HNC multidisciplinary clinic that is
attended by surgical specialists, medical and radiation
oncologists, cancer care nurses, speech pathologists and
dietitians. All patients attending the clinic underwent base-
line swallow and communication screening by a speech
pathologist, and baseline nutrition risk was assessed by a
dietitian using a validated malnutrition risk screening tool.
All patients recommended for radiotherapy +/− systemic
therapy with any head and neck cancer diagnosis irrespect-
ive of subtype are referred to the hospital’s joint radiation
oncology speech pathologist and dietitian HNC clinic. Pa-
tients having 20 or more fractions of radiotherapy (i.e.
4 weeks or more) are invited to attend the allied health
multidisciplinary pre-treatment education session, followed
by weekly individual consultations in the joint speech path-
ologist and dietitian clinic during treatment. Patient’s hav-
ing shorter courses of radiation (i.e. < 20 fractions) are
offered consultation in the clinic, however frequency of
consultations is on an individual basis. In the post treat-
ment setting, patients were scheduled for bi-weekly review
appointments for the first 6 weeks and could remain in the
service for up to 12 months post treatment.
Measures
Local clinical practice was assessed against four selected
recommendations from the COSA guidelines. These
were: 1) the use of a validated malnutrition screening
tool (MST) [15, 16], 2) nutrition assessment using the
Patient-Generated Subjective Global Assessment (PG-SGA),
3) weekly contact with a dietitian during treatment and 4)
post treatment dietitian follow up bi-weekly for 6 weeks.
Prophylactic gastrostomy placement was assessed against
the risk classification of the RBWH guidelines.
Nutritional status was assessed by dietitians using the
global rating of the PG-SGA [17], and weight was mea-
sured on calibrated digital scales. The PG-SGA is a nu-
trition assessment tool that was adapted from the
Subjective Global Assessment (SGA), specifically for
cancer patients. It is based on patients using a check box
format to answer questions regarding recent food intake,
nutrition impact symptoms, activities and function and
short-term weight loss. A physical examination is then
performed by a health professional to assess muscle
wasting, loss of subcutaneous fat and oedema [18].
Measures were taken at baseline (initial contact with
radiation dietitian and speech pathologist), end of treat-
ment, 1 month post treatment (± 1 week) and 3 months
post treatment (± 2 weeks). Gastrostomy dependence
was defined as patients who relied on their gastrostomy
for any nutrition or hydration intake at 6 and 12 months
post completion of treatment. At each assessment, clini-
cians documented a Functional Oral Intake Scale (FOIS)
score that was determined from patient reported typical
intake prior to attending their appointment. This is a
7-point ordinal scale that quantifies restrictions on oral
intake [19, 20].
Data analysis
All data were de-identified and stored in Microsoft Excel.
Statistical analysis of the data was completed using SPSS
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(version 22.0, 2013, IBM Corp) and Microsoft Excel.
Chi-square tests were used to compare categorical vari-
ables, and t tests were used for continuous variables. Sig-
nificance was reported at the P = < 0.05 level.
Results
From the 273 patients referred to the joint dietitian and
speech pathologist clinic over the two-year period, 231
were eligible for inclusion. A further 22 patients were ex-
cluded due to missing data, mainly from patients declining
the speech and dietetics service (n = 9), failing to attend
multiple appointments (resulting in discharge from service
as per local guidelines) (n = 8) or not completing treat-
ment (n = 5). The sample population (N = 209) was pre-
dominantly male (85%), over the age of 65 years (range
28–93 years). Common cancer primary sites included skin
(32%), oropharynx (27%) and oral cavity (22%) (Table 1).
The mean dose of radiation treatment received was
64.8 Gy delivered over 31.9 fractions with 92.3% of pa-
tients receiving a dose between 60 and 70 Gy. In the 6
months before treatment, a total of 77 (36.8%) patients re-
ported prior weight loss, with 2.9% experiencing > 10%
loss of body weight prior to treatment.
Regarding adherence to guideline recommendations, use
of a validated malnutrition screening tool pre-treatment
was met in 86% of cases and the use of a validated nutrition
assessment tool during treatment (PG-SGA) was met for
100% of patients. Weekly review by a dietitian during treat-
ment occurred 80% of the time and 62% of patients were
reviewed bi-weekly for 6 weeks post treatment. In patients
for whom nutrition screening was not completed, this was
mainly due to patient non-attendance at the hospital’s
multidisciplinary HNC clinic where screening takes place.
The main reason (n = 37, 90%) patients were not seen
weekly during treatment was due to failure to attend sched-
uled appointments. In the post-treatment setting, the main
reasons patients were not seen fortnightly included failure
to attend appointments (n = 42, 70%) or clinicians deeming
a review was not clinically indicated (n = 8, 13%). Of the pa-
tients who were not seen fortnightly post treatment, 53%
had primary tumors of the larynx or skin, who together lost
the least amount of weight in the cohort (Table 2).
Of the 72 patients who were identified as high risk as
per the RBWH guidelines, 58 (81%) received a prophy-
lactic gastrostomy. Fourteen patients did not receive a
gastrostomy as they declined the procedure (n = 5) or
the procedure was medically contraindicated and not of-
fered to the patient (n = 9). Of these patients, 86% (n =
12) were malnourished at the end of treatment, 3 pa-
tients accepted reactive nasogastric feeding tubes, and 4
patients had nutrition-related hospital admissions. An
additional 2 patients in the overall cohort (N = 209) re-
ceived a reactive gastrostomy (1 oral cavity patient, 1
oropharynx patient) and 8 patients required reactive
Table 1 Baseline patient characteristics of head and neck
cancer patients treated with radiation therapy at Gold Coast
University Hospital between 1st April 2014 and the 31st of
March 2016
Patient characteristics No. of patients [N, (%)]
Gender
Male 177 (85)
Female 32 (15)
Age (years)
< 50 26 (12.5)
50–65 86 (41)
> 65 97 (46.5)
Prior weight loss
0% 133 (64)
< 5% 51 (24)
5- < 10% 19 (9)
> 10% 6 (3)
Site
Oral cavity 22 (10.5)
Oropharynx 56 (27)
Nasopharynx 8 (4)
Hypopharynx 7 (3)
Larynx 21 (10)
Salivary 19 (9)
Skin primary 67 (32)
Unknown primary 6 (3)
Other 3 (1.5)
T Stage
T0 24 (11.5)
T1 35 (17)
T2 51 (24.5)
T3 37 (17.5)
T4 48 (23)
Tx 12 (5.5)
Other 2 (1)
N Stage
0 54 (25.5)
1 35 (17)
2 112 (53.5)
3 5 (2.5)
Unknown 3 (1.5)
M Stage
0 206 (97.5)
1 3 (1.5)
Treatment
Radiation therapy 50 (24)
Radiation therapy + chemotherapy 96 (46)
Surgery + radiation therapy 54 (26)
Surgery + radiation therapy and chemotherapy 10 (4)
Hofto et al. Cancers of the Head & Neck  (2018) 3:6 Page 3 of 7
nasogastric feeding tube placement (4 oropharynx pa-
tients, 2 salivary patients, 1 nasopharynx patient, 1 un-
known primary).
The average weight loss from baseline at the end of treat-
ment was 5.6 kg (SD 4.5) (6.7%) (p = < 0.001), 7.9 kg (SD
5.5) (8.6%) at one-month post treatment (p = < 0.001)
and 8.9 kg (SD 6.4) (10.3%) 3 months post treatment
(p = < 0.001) (Fig. 1). The average weight loss was
greatest for patients with oral cavity and oropharynx cancers
both at the end of treatment (10.9, 8.8%), and three-months
post treatment (14.7, 12.5%) (Table 2). Weight loss was sta-
tistically significant between oropharyngeal and skin primary
cancers at all time points (p= < 0.001). Additionally, at the
end of treatment, malnutrition rates were statistically higher
(p= < 0.001) in oropharynx patients (n = 41, 77%) in com-
parison to skin primary cancer patients (n = 22, 38%).
Weight loss was not significantly different between pa-
tients who received Cetuximab (n = 32) and patients who
received Cisplatin (n = 64) both at the end of treatment
(p = 0.210) and three-months post treatment (p = 0.954).
The average weight loss for Cetuximab patients at the end
of treatment was 7.3 kg (SD 5.0) (8.9%) and 9.7 kg (SD
6.0) (11.4%) three-months post treatment, compared to
7.4 kg (SD 5.1) (8.6%), and 10.7 kg (SD 6.1) (12.1%)
three-months post treatment for Cisplatin patients. A total
of 18 (28%) patients who received Cisplatin required a
change to Cetuximab during treatment due to toxicity and
23 (36%) of Cisplatin patients planned for 3 high dose cy-
cles either had their dose reduced or third cycle cancelled.
As seen in Table 3, malnutrition rates increased
throughout treatment. There was a statistically significant
difference in the number of patients malnourished at
baseline and the number of patients malnourished at the
end of treatment (p = < 0.001), the number of patients
malnourished one-month post treatment (p = < 0.001) and
the number of patients malnourished 3 months’ post
treatment (p = 0.006).
Changes in type of oral intake as reported by patients and
classified by clinicians completing the FOIS were significant
between baseline and end of treatment (p = < 0.001) and
baseline to one-month post treatment (p = < 0.001). FOIS
scores were not significantly different from baseline to
three-months post treatment (p = 0.538). The average FOIS
score at baseline was 7 (i.e. total oral intake with no res-
trictions), 4.6 at the end of treatment (i.e. heavily
texture-modified diet), 5.6 (texture modified diet) at one–
month post treatment and 6 (i.e. near normal diet with
special preparation of some foods) three-months post
treatment.
Gastrostomy patients (n = 60) had their tube in-situ
for an average of 150 days (range 44–751 days), with 8
(13%) patients being dependent on their tubes at
Table 2 Average weight loss and percentage weight loss by
tumor subsite at the end of treatment and three-months post
treatment
Cancer Site End of treatment
[kg, (SD), (%)]
3 months post treatment
[kg, (SD), (%)]
Oral Cavity 7.9 (4.6) (10.1%) 11.7 (5.3) (14.0%)
Oropharynx 7.5 (4.5) (8.9%) 11.0 (5.9) (12.5%)
Hypopharynx 5.9 (5.0) (7.0%) 7.9 (1.7) (10.9%)
Salivary 4.3 (4.1) (5.7%) 7.1 (3.8) (11%)
Nasopharynx 3.6 (3.0) (4.8%) 3.5 (2.0) (4.8%)
Skin 4.1 (3.9) 5.6 (4.8%) 6.0 (6.1) (6.8%)
Larynx 2.6 (3.6) (2.9%) 4.5 (4.9) (4.7%)
55
60
65
70
75
80
85
90
95
100
Baseline End of treatment 1 month post 3 months post
W
ei
gh
t (
kg
)
Fig. 1 Average weight change for HNC patients from baseline to three months post treatment. Relationship between time and weight loss over
a period of three months in head and neck cancer patients over the duration of radiation treatment. Weight change was measure in kilos (kg),
with large variations seen at each time point
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6 months post treatment and 2 patients (3%) dependent
12 months post treatment. Gastrostomy patients lost an
average of 7.7 kg (9.4%) whilst on treatment and 11.5 kg
(13.5%) from baseline to three-months post treatment.
A total of 55 (26%) patients in the cohort had an un-
planned hospital admission during treatment, of which 14
(25%) were nutrition-related. The average length of stay
was 4.6 days, with common admission reasons including
decreased oral intake and anorexia. Of the 60 gastrostomy
patients, 24 (40%) required unplanned admissions during
treatment, of which 5 (21%) were nutrition-related.
Discussion
Significant weight loss and malnutrition still occur in
HNC patients, despite the introduction of best-practice
nutritional guidelines and treatment advances in radi-
ation oncology. Little is known however, how well guide-
lines are able to be integrated into clinical practice. This
study shows that despite good adherence to guidelines
selected for comparison, clinically significant weight loss
and malnutrition are still highly prevalent. This raises
the question as to whether current recommendations for
dietetic care both during and post-treatment should be
reviewed, particularly for tumor sites which are known
to put patients at higher risk for nutritional inadequacy,
including those which originate in the oropharynx and
oral cavity region.
This study reports an 81% adherence rate to the RBWH
HNC risk category guidelines for prophylactic gastros-
tomy placement, interestingly higher than the 75% re-
ported in 2008 by RBWH [5]. With regards to patient
attendance, it was apparent in the current study the main
reason patients were not seen as per guideline frequency
was due to patient failure to attend. Compliance with ap-
pointments in this patient group has previously been re-
ported to be poor [21], with some dietetic clinics stating a
non-attendance rate as high as 27% [7]. Non-compliance
is more common in patients with mental illnesses, sub-
stance abuse, and those who do not feel that dietetic care
is a central component of treatment [21].
The average time gastrostomy patients had their feed-
ing tube in-situ (5 months) was substantially shorter
than that reported in other studies, with Crombie et al.,
[22] reporting the average length a patient had their tube
in-situ was 7 months and Jack et al., [23] greater than
21 months. This may be due to some services having
protocols that recommend gastrostomy tubes remain in
for various amounts of time, depending on the treating
institutions services and specialist support [13]. Gastros-
tomy tube dependence is also linked with swallowing
outcomes, with literature demonstrating those who are
tube-dependent long-term often having minimal swallow
function [13]. Stimulation of musculature involved in
swallowing has demonstrated to assist patients in return-
ing to a full and non-texture modified diet more quickly
post treatment [24]. Although patients in this study
showed a decline in their reported ability to consume a
full-textured diet during treatment, at three-months post
treatment, patient reported dietary restrictions had al-
most returned to baseline levels in the majority of pa-
tients. Decline in the ability to consume a full-textured
diet during intensive treatment may reflect a decline in
swallow function. Diet restrictions returning to baseline
may be in part attributable to the intensive support and
prophylactic swallowing exercises patients received as
part of the joint dietetic and speech pathologist service.
Weight loss prior to treatment is a prognostic factor
for overall survival and is one of the biggest indicators of
malnutrition [25]. Malnutrition is strongly related to de-
creased quality of life, increased unplanned hospital ad-
missions and decreased effectiveness of treatment [7]
[8]. The number of patients malnourished both at the
end of treatment (56%) and three-months post treatment
(30%) is comparable to that demonstrated in the litera-
ture. A study by Jager-Wittenaar et al., [26] on oral cav-
ity and oropharyngeal cancer patients, reported that
during treatment overall malnutrition rates were 16, and
25% 3 months post treatment [26]. This is similar to van
de Berg et al., [27] who conducted a study with squa-
mous cell carcinoma patients, demonstrating even with
individual dietary care, 18% of patients were malnour-
ished while receiving treatment and 10.5% were mal-
nourished in the rehabilitation phase two-months post
treatment. The differences seen between the current
study and both Jager-Wittenaar et al., [26] and van de
Berg et al. [27] in malnutrition rates may be due to both
the timing of measured outcomes and the difference in
definition of malnutrition, with both studies using per-
centage weight loss to define malnutrition and the
current study using the PG-SGA tool.
Clinically significant weight loss (> 10%) prior to treat-
ment was reported by 2.9% of the cohort, less than the
6.6% reported by Brown et al., [5] and the 5% reported
by Languis et al., [25]. Weight loss during treatment
Table 3 Patient Generated-Subjective Global Assessment (PG-
SGA) global ratings of head and neck cancer patients from
baseline to three-months post treatment
Time point Well-nourished
(PG-SGA A) [N, (%)]
Malnourished
(PG-SGA B + C)
[N, (%)]
Baseline (n = 209) 177 (85) 32 (15)
End of Treatment (n = 183) 80 (44) 103 (56)
One month post treatment
(n = 144)
66 (46) 79 (54)
Three months post treatment
(n = 124)
87 (70) 37 (30)
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(average 6.7%) was similar to a study by Langius et al.,
[25] where patients lost 6.1% body weight during treat-
ment, although greater than that reported by Paccagnella
et al., [28] where patients had lost 4.6% of body weight
at the end of treatment. The current study also demon-
strates that despite continued dietetic intervention, at 3
months post treatment, patients continued to lose
weight. This highlights the potential need for increased
length of intensive monitoring (bi-weekly) post treat-
ment or additional community support. Weight loss be-
tween patients in the current study who received
Cisplatin and Cetuximab was not statistically significant
both during and post-treatment. It should however be
noted, that a large proportion of patients who were
planned to receive Cisplatin either did not complete
their full course of chemotherapy or changed to Cetuxi-
mab to due treatment-related toxicities.
There are currently few studies that demonstrate the
difference in weight loss between tumor sites in HNC,
despite it being recognised that some tumor sites are at
higher risk nutritionally [26]. Weight loss for skin pri-
mary HNC patients in particular, is underrepresented in
the literature, with some studies not including these tu-
mors in the classification of HNC or grouping these into
the ‘other’ category [13, 22, 24, 25, 29]. Consistent with
the RBWH guidelines, this demonstrates that those with
HNC skin cancer tumors are generally not considered to
be at high risk nutritionally. A study by Jager-Wittenaar
et al., [29] demonstrated that critical weight loss (> 5% in
1 month or > 10% in 6 months) was seen in 8% of pa-
tients with skin, salivary and thyroid tumors, compared
to 34% of patients with oropharynx/oral cavity tumors.
These results are comparable to those presented in the
current study with oropharynx patients losing on aver-
age 12.5%, oral cavity patients losing 14.7% and skin can-
cer patients losing 6.0% of body weight at three-months
post treatment. Significant differences (p = < 0.001) in
weight loss for oral cavity (10%) and oropharynx (11%)
patients compared to weight loss in patients with laryn-
geal tumors (5%) has also been demonstrated in a study
by Ehrsson et al., [30]. Likewise, in a study by Nourissat
et al., [31] critical weight loss (> 5% during radiation
therapy) was reported in 62.9% of oral cavity or orophar-
ynx patients. These studies did not include skin cancer
tumors in analysis. Tumor location can then be seen to
have a significant impact on both weight loss and nutri-
tional status. As nutritional status exerts its effects not
only on the patient, but the healthcare system and diet-
etic services as well, the relationship between tumor lo-
cation and weight loss warrants further investigation.
Additionally, a review of current guidelines to include
more intense nutritional care and updated care path-
ways for patients at higher risk of clinically significant
weight loss (e.g. oropharyngeal and oral cavity tumors)
may be justified. Streaming care by tumor site may also
reduce unneeded or unnecessary appointments and
allow specialised clinicians more time with high risk
patients.
The strengths of this study are that the primary re-
searcher who reviewed the outcomes of patients treated
at the hospital was not involved in any clinical care of
patients, reducing potential researcher bias. The study
also had a relatively large sample size and a representa-
tive sample of patients recruited. This study is inherently
limited by its retrospective, single-institution design.
Furthermore, we do not have data on all patients across
all the time points, for reasons that include patients
transferring back to a local service, thus making it diffi-
cult to draw stronger conclusions. A prospective study
could overcome this by gathering data of enrolled pa-
tients ongoing from outside institutions, should enrolled
patients choose to receive follow-up care closer to home.
The study is also limited in that it does not address pa-
tient adherence to dietary optimization at home or
quantify energy and protein intake in comparison to best
practice guidelines. Non-adherence to dietetic recom-
mendations may have resulted in higher rates of malnu-
trition and more significant weight loss. Data on energy
and protein intake quantified against guideline recom-
mendations would also demonstrate if patients were
meeting their nutrition requirements and still experien-
cing significant weight loss or malnutrition.
Conclusion
The use of evidenced-based guidelines for HNC enables
the early identification of patients at nutritional risk and
provides care pathways for clinicians to follow. Our study
supports the use of current Australian guidelines as a
method of identifying patients who may need enteral feed-
ing, however suggests that streaming care, in particular
for dietetic monitoring by tumor site has the potential to
further improve patient outcomes and could be a better
use of finite healthcare resources. Continued weight loss
in this population post treatment also suggests that per-
haps bi-weekly follow up should continue to occur for
greater than 6 weeks post treatment. Suggestions for fu-
ture studies include the trial of care pathways by tumor
site to explore weight loss and malnutrition in subgroups
of the HNC population, and assessing patient adherence
to nutrition recommendations (energy and protein intake)
as directed by the dietitian.
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